Ianalumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | BAFF receptor |
| Clinical data | |
| Other names | VAY736 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ianalumab (INN;[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus.[2][3][4]
This drug is being developed by Novartis. As of 2021, ianalumab is undergoing Phase II/III trials.[5][6]
References
- ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- ↑ "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG.
- ↑ van den Hoogen LL, van Laar JM (February 2020). "Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome". Best Practice & Research. Clinical Rheumatology. 34 (1): 101485. doi:10.1016/j.berh.2020.101485. PMID 32067925.
- ↑ Narain S, Berman N, Furie R (November 2020). "Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis". Current Opinion in Rheumatology. 32 (6): 609–616. doi:10.1097/BOR.0000000000000754. PMID 33002950. S2CID 222150641.
- ↑ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
- ↑ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.